Effective date. 

## SEC. 705. TECHNICAL AMENDMENTS. 

(a) PUBLIC HEALTH SERVICE ACT.—Title III (42 U.S.C. 241 et seq.) is amended— 

(b) PUBLIC HEALTH SECURITY GRANTS.—Section 319C–1(b)(2) (42 U.S.C. 247d–3a(b)(2)) is amended— 

(c) EMERGENCY USE INSTRUCTIONS.—Subparagraph (A) of sec- tion 564A(e)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–3a(e)(2)) is amended by striking ‘‘subsection (a)(1)(C)(i)’’ and inserting ‘‘subsection (a)(1)(C)’’. 

(d) PRODUCTS HELD FOR EMERGENCY USE.—Section 564B(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb– 3b) is amended— 

(e) TRANSPARENCY.—Section 507(c)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357(c)(3)) is amended— 

(B) as of the date of the enactment of this Act, remains in the care of the Department of Health and Human Serv- ices; and 

(C) can be safely reunited with such parent or guardian; and 

(2) a report on challenges and deficiencies related to the oversight of, and care for, unaccompanied alien children and appropriately reuniting such children with their parents or guardians, and the actions taken to address any challenges and deficiencies related to unaccompanied alien children in the custody of the Department of Health and Human Services, including deficiencies identified and publicly reported by Con- gress, the Government Accountability Office, or the inspectors general of the Department of Health and Human Services or other Federal departments. 

(1) in paragraphs (1) and (5) of section 319F–1(a) (42 U.S.C. 247d–6a(a)), by striking ‘‘section 319F(h)’’ each place such term appears and inserting ‘‘section 319F(e)’’; and 

(2) in section 319K(a) (42 U.S.C. 247d–7d(a)), by striking ‘‘section 319F(h)(4)’’ and inserting ‘‘section 319F(e)(4)’’. 

(1) in subparagraph (C), by striking ‘‘individuals,,’’ and inserting ‘‘individuals,’’; and 

(2) in subparagraph (F), by striking ‘‘make satisfactory annual improvement and describe’’ and inserting ‘‘makes satis- factory annual improvement and describes’’. 

(1) in subparagraph (B), by inserting a comma after ‘‘505’’; and 

(2) in subparagraph (C), by inserting ‘‘or section 564A’’ before the period at the end. 

(1) by striking ‘‘Nothing in’’ and inserting the following: ‘‘(A) IN GENERAL.—Nothing in’’; 

(2) by inserting ‘‘or directing’’ after ‘‘authorizing’’; 

(3) by striking ‘‘disclose any’’ and inserting ‘‘disclose— ‘‘(i) any’’; 

(4) by striking the period and inserting ‘‘; or’’; and 

(5) by adding at the end the following: 

‘‘(ii) in the case of a drug development tool that may be used to support the development of a qualified countermeasure, security countermeasure, or qualified pandemic or epidemic product, as defined in sections 319F–1, 319F–2, and 319F–3, respectively, of the Public Health Service Act, any information that the 

